# Lignan

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lignan
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 4 / 10
**Category:** Compound
**Also Known As:** Secoisolariciresinol diglucoside, SDG, Flaxseed lignans, Phytoestrogen lignans, Plant lignans, Enterolignans, Polyphenolic lignans, Flax lignans

## Overview

Lignans are polyphenolic phytoestrogens found in flaxseed, sesame, and whole grains that are converted by gut bacteria into the mammalian lignans enterodiol and enterolactone. These metabolites bind weakly to estrogen receptors (ERα and ERβ) and modulate sex hormone [metabolism](/ingredients/condition/weight-management), contributing to their studied effects on hormone-sensitive conditions and [cardiovascular](/ingredients/condition/heart-health) markers.

## Health Benefits

• May reduce breast tissue proliferation markers (Ki-67) in premenopausal women at risk for breast cancer, though clinical significance remains unclear (Phase IIB RCT, n=180, PMID: 32312713)
• Potentially reduces [inflammatory](/ingredients/condition/inflammation) marker C-reactive protein in hypercholesterolemic subjects (small RCT, PMID: 18502107)
• May improve breast cancer prognosis in postmenopausal women according to observational data (meta-analysis with high heterogeneity, PMCID: PMC8040718)
• Ineffective for hot flash reduction despite Phase III trial testing (n=410 mg/day, PMID: 21900849)
• Modulates estrogen-related gene expression including ERα downregulation (qRT-PCR evidence in 77 subjects, PMID: 32312713)

## Mechanism of Action

Gut microbiota convert plant lignans such as secoisolariciresinol diglucoside (SDG) into the mammalian lignans enterodiol and enterolactone, which act as selective estrogen receptor modulators (SERMs) with preferential affinity for ERβ over ERα. Enterolactone also inhibits aromatase (CYP19A1) and 17β-hydroxysteroid dehydrogenase, reducing local estrogen biosynthesis and altering the estradiol-to-estrone ratio. Additionally, lignans upregulate sex hormone-binding globulin (SHBG) synthesis in the liver, decreasing bioavailable estradiol and [testosterone](/ingredients/condition/hormonal).

## Clinical Summary

A Phase IIB RCT (n=180, PMID: 32312713) found that flaxseed lignan supplementation reduced Ki-67 breast tissue proliferation markers in premenopausal women at elevated breast cancer risk, though clinical significance remains uncertain. Small RCTs in hypercholesterolemic subjects suggest lignans reduce C-reactive protein (CRP), with some trials using 300–600 mg/day of SDG from flaxseed, though sample sizes limit generalizability. Evidence for [LDL cholesterol](/ingredients/condition/heart-health) reduction is modest and inconsistent across meta-analyses. Overall, the evidence base is promising but requires larger, longer-duration trials to confirm clinical endpoints.

## Nutritional Profile

Lignans are polyphenolic phytoestrogens, not macronutrients, and contribute negligible caloric value. They are found most concentrated in flaxseed (~300–500 mg secoisolariciresinol diglucoside (SDG) per 100g), sesame seeds (~29–573 mg/100g as sesaminol and sesamolin), whole grains (~0.5–3 mg/100g), and some legumes. The primary dietary lignan precursor is SDG, which gut bacteria convert to the active mammalian lignans enterodiol and enterolactone (bioavailability highly dependent on [gut microbiome](/ingredients/condition/gut-health) composition — estimated conversion efficiency varies 10–50% between individuals). Lignans are not a source of vitamins or minerals inherently, though lignan-rich foods like flaxseed also supply omega-3 ALA (~22g/100g), magnesium (~392mg/100g), and fiber (~27g/100g). Absorption is enhanced in the presence of dietary fat; bioavailability is significantly reduced by antibiotic use that disrupts gut microbiota responsible for SDG-to-enterolactone conversion.

## Dosage & Preparation

Clinically studied doses include: SDG extract (standardized to 80-90% SDG): 50 mg/day for up to 12 months; Flax lignan complex powder: 410-500 mg/day in food matrices. Study durations ranged from 6-12 months with no established therapeutic range. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Lignans are generally well tolerated at typical supplemental doses (300–600 mg/day SDG equivalent), with the most commonly reported side effects being mild gastrointestinal discomfort such as bloating and loose stools due to fiber co-ingestion in whole food sources. Because lignans exhibit weak estrogenic and anti-estrogenic activity, women with estrogen receptor-positive (ER+) breast cancer or those on hormone replacement therapy (HRT) or tamoxifen should consult a physician before supplementing, as pharmacodynamic interactions are plausible. Lignans may potentiate anticoagulant effects when combined with warfarin by altering CYP2C9-mediated [metabolism](/ingredients/condition/weight-management), warranting INR monitoring. Pregnancy safety has not been established in controlled human studies; high-dose supplementation is not recommended during pregnancy or lactation.

## Scientific Research

The most robust evidence comes from a Phase IIB multicenter RCT (PMID: 32312713) testing 50 mg/day SDG in 180 premenopausal women at breast cancer risk, showing modest Ki-67 reduction but no significant between-group difference. A Phase III trial (PMID: 21900849) found no efficacy for hot flashes despite good tolerability, while a meta-analysis (PMCID: PMC8040718) suggests potential prognostic benefits in breast cancer survivors with considerable study heterogeneity.

## Historical & Cultural Context

While flaxseed has been used in traditional European, Chinese, and Ayurvedic medicine for over 2000 years for constipation and [hormonal balance](/ingredients/condition/hormonal), lignans were not specifically isolated historically. Modern interest in isolated lignans stems from 1990s cancer prevention research rather than traditional use.

## Synergistic Combinations

Flaxseed fiber (mucilage) pairs synergistically with lignans by slowing intestinal transit and extending gut bacterial exposure time, improving SDG-to-enterolactone conversion efficiency. [Probiotic](/ingredients/condition/gut-health)s (specifically Lactobacillus acidophilus and Bifidobacterium longum strains) directly enhance lignan bioconversion by upregulating the bacterial enzymes responsible for converting SDG into active enterodiol and enterolactone, amplifying circulating levels by up to 3-fold in some studies. Omega-3 fatty acids (EPA/DHA) complement lignans through parallel anti-[inflammatory pathway](/ingredients/condition/inflammation)s — lignans suppress NF-κB-mediated cytokine production while omega-3s modulate eicosanoid synthesis via COX/LOX inhibition, producing additive reductions in CRP. Additionally, vitamin E (tocopherols) found co-occurring in sesame acts as a complementary [antioxidant](/ingredients/condition/antioxidant), protecting lignan metabolites from oxidative degradation and extending their half-life in circulation.

## Frequently Asked Questions

### What is the best dietary source of lignans?

Flaxseed (linseed) is by far the richest dietary source of lignans, providing approximately 75–800 mg of secoisolariciresinol diglucoside (SDG) per 100 g of ground seed. Sesame seeds, rye bran, and certain berries such as strawberries also contribute meaningful amounts, but at concentrations roughly 10–100 times lower than flaxseed.

### How much lignan should I take per day for health benefits?

Clinical trials investigating cardiovascular and breast health outcomes have most commonly used doses of 300–600 mg/day of secoisolariciresinol diglucoside (SDG) from flaxseed, roughly equivalent to 30–40 g of ground flaxseed daily. No universally established optimal dose exists, and effective amounts likely vary based on individual gut microbiome composition, which determines conversion efficiency to active enterolactone and enterodiol.

### Do lignans affect estrogen levels in women?

Yes, lignans modulate estrogen metabolism through multiple mechanisms: their gut-derived metabolite enterolactone inhibits aromatase (CYP19A1), reducing estrogen biosynthesis, and increases hepatic production of sex hormone-binding globulin (SHBG), lowering free estradiol. However, they also bind weakly to ERβ with mild agonist activity, making their net estrogenic effect highly context-dependent on baseline hormone status and gut microbiome efficiency.

### Are lignan supplements safe for women with breast cancer?

The interaction between lignan supplementation and breast cancer treatment is complex and not fully resolved. Some observational data associate higher circulating enterolactone levels with improved breast cancer prognosis, and the Ki-67 RCT (PMID: 32312713) showed reduced proliferation markers in high-risk premenopausal women. However, because lignans can exert weak estrogenic activity via ERβ, women with ER+ breast cancer or on endocrine therapies like tamoxifen or aromatase inhibitors should only supplement under oncologist supervision.

### What is the difference between plant lignans and mammalian lignans?

Plant lignans such as secoisolariciresinol diglucoside (SDG), matairesinol, and pinoresinol are the precursor compounds found in foods and supplements that are not biologically active as phytoestrogens in their native form. Upon ingestion, colonic bacteria (notably Clostridium and Lactonifactor species) biotransform them into the mammalian lignans enterodiol and enterolactone, which are the pharmacologically active metabolites that bind estrogen receptors and inhibit steroidogenic enzymes.

### Does lignan supplementation interact with hormone replacement therapy (HRT) or tamoxifen?

Lignans may have mild estrogenic activity and could theoretically interact with HRT or tamoxifen, though clinical evidence of problematic interactions is limited. Anyone taking hormone-based cancer treatments or HRT should consult their oncologist or healthcare provider before adding lignan supplements, as individual risk factors vary. Most concern centers on very high doses rather than dietary lignan intake.

### What is the current strength of clinical evidence supporting lignan use for breast cancer prevention?

Current evidence is preliminary and mixed, with most studies showing modest effects on surrogate markers like Ki-67 (cell proliferation) rather than actual cancer outcomes. A Phase IIB randomized controlled trial (n=180) showed potential benefit in premenopausal women at risk, but larger, longer-term studies are needed to establish clinical significance. Observational data in postmenopausal women suggest possible benefits for prognosis, but this cannot establish cause-and-effect relationships.

### Who is most likely to benefit from lignan supplementation based on current research?

Premenopausal women with elevated breast cancer risk appear to be the primary focus of current research, though evidence remains preliminary. Postmenopausal women may derive potential benefits according to observational studies, though this requires confirmation in controlled trials. Individuals with elevated inflammatory markers (C-reactive protein) or hypercholesterolemia may also benefit based on small preliminary studies, but individual suitability should be assessed with a healthcare provider.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*